Phytochemicals targeting NF-κB signaling: Potential anti-cancer interventions
- PMID: 35811622
- PMCID: PMC9257438
- DOI: 10.1016/j.jpha.2021.07.002
Phytochemicals targeting NF-κB signaling: Potential anti-cancer interventions
Abstract
Nuclear factor κB (NF-κB) is a ubiquitous regulator of the signalome and is indispensable for various biological cell functions. NF-κB consists of five transcription factors that execute both cytoplasmic and nuclear signaling processes in cells. NF-κB is the only signaling molecule that governs both pro- and anti-apoptotic, and pro- and anti-inflammatory responses. This is due to the canonical and non-canonical components of the NF-κB signaling pathway. Together, these pathways orchestrate cancer-related inflammation, hyperplasia, neoplasia, and metastasis. Non-canonical NF-κB pathways are particularly involved in the chemoresistance of cancer cells. In view of its pivotal role in cancer progression, NF-κB represents a potentially significant therapeutic target for modifying tumor cell behavior. Several phytochemicals are known to modulate NF-κB pathways through the stabilization of its inhibitor, IκB, by inhibiting phosphorylation and ubiquitination thereof. Several natural pharmacophores are known to inhibit the nuclear translocation of NF-κB and associated pro-inflammatory responses and cell survival pathways. In view of this and the high degree of specificity exhibited by various phytochemicals for the NF-κB component, we herein present an in-depth overview of these phytochemicals and discuss their mode of interaction with the NF-κB signaling pathways for controlling the fate of tumor cells for cancer-directed interventions.
Keywords: Cancer; Chemoprevention; Inflammation; Phytochemicals; Transcription factor.
© 2021 The Authors.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Figures
![Image 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9257438/bin/ga1.gif)
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9257438/bin/gr1.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9257438/bin/gr2.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9257438/bin/gr3.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9257438/bin/gr4.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9257438/bin/gr5.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9257438/bin/gr6.gif)
![Fig. 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9257438/bin/gr7.gif)
![Fig. 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9257438/bin/gr8.gif)
Similar articles
-
Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy.Front Oncol. 2022 Mar 1;12:834072. doi: 10.3389/fonc.2022.834072. eCollection 2022. Front Oncol. 2022. PMID: 35299751 Free PMC article.
-
Protein Kinase-Mediated Decision Between the Life and Death.Adv Exp Med Biol. 2021;1275:1-33. doi: 10.1007/978-3-030-49844-3_1. Adv Exp Med Biol. 2021. PMID: 33539010
-
NF-κB Signaling in Ovarian Cancer.Cancers (Basel). 2019 Aug 15;11(8):1182. doi: 10.3390/cancers11081182. Cancers (Basel). 2019. PMID: 31443240 Free PMC article. Review.
-
Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease.Pharmacol Res. 2018 Mar;129:262-273. doi: 10.1016/j.phrs.2017.11.030. Epub 2017 Nov 24. Pharmacol Res. 2018. PMID: 29179999 Review.
-
The IkappaB kinase complex: master regulator of NF-kappaB signaling.Immunol Res. 2008;42(1-3):3-18. doi: 10.1007/s12026-008-8025-1. Immunol Res. 2008. PMID: 18626576 Free PMC article. Review.
Cited by
-
Pleiotropic attenuating effect of Ginkgo biloba against isoprenaline-induced myocardial infarction via improving Bcl-2/mTOR/ERK1/2/Na+, K+-ATPase activities.Chin Herb Med. 2023 Nov 28;16(2):282-292. doi: 10.1016/j.chmed.2023.11.001. eCollection 2024 Apr. Chin Herb Med. 2023. PMID: 38706831 Free PMC article.
-
Antimicrobial, Probiotic, and Immunomodulatory Potential of Cannabis sativa Extract and Delivery Systems.Antibiotics (Basel). 2024 Apr 17;13(4):369. doi: 10.3390/antibiotics13040369. Antibiotics (Basel). 2024. PMID: 38667045 Free PMC article.
-
Drug repurposing for cancer therapy.Signal Transduct Target Ther. 2024 Apr 19;9(1):92. doi: 10.1038/s41392-024-01808-1. Signal Transduct Target Ther. 2024. PMID: 38637540 Free PMC article. Review.
-
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents.Cell Commun Signal. 2024 Apr 15;22(1):228. doi: 10.1186/s12964-024-01607-9. Cell Commun Signal. 2024. PMID: 38622735 Free PMC article. Review.
-
Characterisation and evaluation of physical properties of AH-Plus sealer with and without the incorporation of petasin, pachymic acid, curcumin and shilajit-an invitro study.BMC Oral Health. 2024 Mar 19;24(1):352. doi: 10.1186/s12903-024-04108-w. BMC Oral Health. 2024. PMID: 38504287 Free PMC article.
References
-
- Sen R., Baltimore D. Inducibility of NF-κB immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism. Cell. 1986;47:921–928. - PubMed
-
- Baeuerle P.A., Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor. Cell. 1988;53:211–217. - PubMed
-
- Gilmore T.D. NF-κB, KBF1, dorsal, and related matters. Cell. 1990;62:841–843. - PubMed
-
- Gilmore T.D. Introduction to NF-κB: Players, pathways, perspectives. Oncogene. 2006;25:6680–6684. - PubMed
Publication types
LinkOut - more resources
Full Text Sources